CHARGED ALPHA
Stock Analysis
Stock Library / ARGX
ARGX Unclassified Latest YouTube: Q2 2026

ARGX

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

argenx Stock (ARGX): VYVGART Sales Jump 60% and It’s Now PROFITABLE — Here’s Why We Say BUY

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q2 2026
Podcast available
Yes
Current price
$924.60
+72.88 (+8.56%)
Trailing / Forward P/E
41.04x
Forward: 24.86x
Market cap / Volume
Volume:
Revenue / Earnings Growth
62.6%
Earnings: 114.0%
Margins
30.0% op
Gross: 58.1% · Net: 31.4%
Balance sheet
Debt / Equity: 0.6
52-week range / Beta
$577.04 - $953.58
Beta: -0.02
Analyst target
$1056.43
Upside: 14.3%
Cash / shareholder return
Dividend yield: —

Company context

Industry: Biotechnology
Country: Netherlands
Employees:
Price to book: 195.33x
Return on equity:
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Price chart

Market context for ARGX

Competitive view

ARGX vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

ARGX latest YouTube video thumbnail YouTube
ARGX
ARGX
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Danaher Corporation latest YouTube video thumbnail YouTube
Danaher Corporation
DHR
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
ADBE latest YouTube video thumbnail YouTube
ADBE
ADBE
Latest video
Q2 FY2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
ARGX
$57.84B
ARGX
DHR
$135.32B
Danaher Corporation
ADBE
$84.34B
ADBE
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
ARGX
41.0x
ARGX
DHR
34.3x
Danaher Corporation
ADBE
12.1x
ADBE
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
ARGX
24.9x
ARGX
DHR
20.8x
Danaher Corporation
ADBE
7.7x
ADBE
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
ARGX
62.6%
ARGX
DHR
5.5%
Danaher Corporation
ADBE
12.7%
ADBE
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
ARGX
114.0%
ARGX
DHR
59.7%
Danaher Corporation
ADBE
7.9%
ADBE
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
ARGX
30.0%
ARGX
DHR
19.8%
Danaher Corporation
ADBE
35.3%
ADBE
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
ARGX
58.1%
ARGX
DHR
58.8%
Danaher Corporation
ADBE
89.4%
ADBE
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
ARGX
31.4%
ARGX
DHR
15.9%
Danaher Corporation
ADBE
28.7%
ADBE
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
ARGX
ARGX
DHR
7.6%
Danaher Corporation
ADBE
63.0%
ADBE
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
ARGX
ARGX
DHR
3.2%
Danaher Corporation
ADBE
10.9%
ADBE
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
ARGX
0.64x
ARGX
DHR
52.97x
Danaher Corporation
ADBE
61.44x
ADBE
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
ARGX
ARGX
DHR
1.65x
Danaher Corporation
ADBE
0.75x
ADBE
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
ARGX
-0.02
ARGX
DHR
0.82
Danaher Corporation
ADBE
1.43
ADBE
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
ARGX
ARGX
DHR
0.8%
Danaher Corporation
ADBE
ADBE
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
ARGX
14.3%
ARGX
DHR
18.8%
Danaher Corporation
ADBE
27.1%
ADBE

Related research

Non-quarter videos featuring ARGX

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-23

argenx (ARGX): VYVGART +60% & Now PROFITABLE — Buy? #Shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

Episode timeline

Episode archive for ARGX

Each row is one earnings episode with every verified platform link available.

Q2 2026
Episode live
Published youtube podcast complete
argenx Stock (ARGX): VYVGART Sales Jump 60% and It’s Now PROFITABLE — Here’s Why We Say BUY
Quarterly earnings-analysis entry for ARGX. Use the links on the right to open the video or podcast episode.